洞察市场格局
解锁药品研发情报

客服电话

400-9696-311

医药数据查询

Velocity

成立时间：2008-09-01

公司官网：http://velocity.uwaterloo.ca/

基本信息：

Velocity is a leading entrepreneurship program at the University of Waterloo and the largest free startup incubator in the world. From idea to product development to commercialization, Velocity provides the knowledge, tools, space and network that startups and entrepreneurs need for success. The Velocity Fund is a grant program for startups that offers $375,000 in equity-free funding each year to local startups through its Velocity Fund $25K and Velocity Fund $5K programs at the University of Waterloo. The Velocity Garage incubator is home base to 80+ early-stage startups building technology-based businesses in the heart of Waterloo Region. Velocity Start is workspace on-campus at the University of Waterloo for people who want to learn about entrepreneurship and collaborate with like-minded people. Resources include lounge and workspace, booking space, weekly workshops, a makerspace with 3D printers and hand tools, startup coaching, and Problem Lab archives to help students identify big problems worth solving. Velocity Science is a partnership between Velocity and the University of Waterloo Faculty of Science, providing students interested in building a science startup with the right tools and resources to initiate and develop world-class science companies. The Velocity Residence provides a unique opportunity for University of Waterloo students to live in an innovative and entrepreneurial environment right on campus. Students are given access to the latest technologies and the opportunity to learn from a great network of mentors and entrepreneurs.

机构画像：

主投领域：

应用技术：

信息技术
健康管理

机构动态

MedaSystems 获得种子轮融资，实现全球研究性药物可及性的现代化

2023-10-12 20:00:00

MedaSystems，一家专注于为患者提供预批准药物访问的药企-医生网络开发者，已完成种子轮融资。投资方包括有成功创办和资助SaaS健康公司的经验的风险投资家和天使投资者，如Veeva Systems、Vlocity和Nomadic Systems的创始人Young Sohn，以及位于巴塞罗那的健康科技风险投资公司nina.capital和公司管理团队成员。MedaSystems的SaaS平台简化了医疗事务、临床运营、监管和物流团队内部以及医生及其团队外部的协作，快速处理治疗咨询并捕捉真实世界数据。该平台为各方带来显著利益，CEO Fiona Smythe表示，这笔资金支持了公司让生命-saving治疗更容易获得，并支持新疗法的研发，同时支持真实世界数据的捕捉、自动化和机器学习功能。此外，平台还涉及扩展访问（Expanded Access）项目，为那些已经耗尽标准治疗且不符合临床试验条件的严重或危及生命的患者提供未获得当地监管机构授权的实验性疗法的访问。